Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
5Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Alumis Inc. (ALMS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
3Distinct source URLs
4High confidence
0.774Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Alumis Inc. Suppliers
Ticker
Name
Confidence
Evidence
FRONTHERA-U-S-HOLDINGS-INC
FRONTHERA-U-S-HOLDINGS-INC
90%
In March 2021, the Company entered into a stock purchase agreement to acquire FronThera U.S. Holdings, Inc. and its wholly owned subsidiary, FronThera U.S. Pharmaceuticals LLC.
available for physicians to prescribe. After that, the MHLW lists its National Health Insurance price within 60 days (or 90 days at the latest) from the approval, and physicians can obtain reimbursem…
Reciprocal relationship from ORANY graph: Reciprocal relationship from ALMS graph: available for physicians to prescribe. After that, the MHLW lists its National Health Insurance price within 60 days…
Alumis Inc. Customers
Ticker
Name
Confidence
Evidence
KAKEN
KAKEN
92%
All of the Company's revenues are currently earned under its license and collaboration agreement with Kaken.
Reciprocal relationship from CLYM graph: Reciprocal relationship from ALMS graph: Reciprocal relationship from CLYM graph: Reciprocal relationship from ALMS graph: Reciprocal relationship from CLYM g…
ted ACELYRIN stock options and RSUs continue to vest in accordance with their original terms. Performance RSUs were deemed to have 100 % satisfied their performance conditions and will vest in two eq…
FRONTHERA-U-S-HOLDINGS-INC
FRONTHERA-U-S-HOLDINGS-INC
62%
ment timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relati…
FRONTHERA-U-S-PHARMACEUTICALS-LLC
FRONTHERA-U-S-PHARMACEUTICALS-LLC
62%
ment timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relati…
Alumis Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ALMS-DEBT
Debt stack $35.7M
90%
Market cache reports total debt of $35.7M.
Alumis Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Alumis Inc..
Alumis Inc. Ownership
Holder
Name
Confidence
Evidence
ALMS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 199 tracked holders.
